Clinical Trials
20 trialsNCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT07234162 2025-11-18
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06072131 2025-10-23
CRESCENDO
Acrotech Biopharma Inc.
Phase 3 Recruiting
NCT02680795 2025-10-20
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Acrotech Biopharma Inc.
Phase 1 Completed
NCT04184869 2023-05-03
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Acrotech Biopharma Inc.
Phase 1 Completed
NCT00865969 2021-10-29
PTCL
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT01310244 2020-01-06
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT01583777 2020-01-03
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01839097 2020-01-03
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Acrotech Biopharma Inc.
Phase 1 Completed
NCT02679131 2019-11-20
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
Phase 1 Terminated
NCT01317927 2015-09-23
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
Spectrum Pharmaceuticals, Inc
Phase 1 Completed
NCT00274651 2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2 Terminated
NCT00421889 2015-07-28
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Phase 1/2 Completed
NCT00873119 2015-07-28
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Valerio Therapeutics
Phase 2 Completed
NCT00878722 2015-07-28
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Valerio Therapeutics
Phase 1/2 Completed
NCT00878800 2015-07-28
A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas
Valerio Therapeutics
Phase 1/2 Completed
NCT00131261 2015-07-08
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Valerio Therapeutics
Phase 2 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00431340 2015-07-08
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Valerio Therapeutics
Phase 2 Terminated